Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
May warrant caution selecting antiarrhythmics in remodeled AF; leaves open targeted therapies addressing ion-channel changes.
Atrial fibrillation (AF) is the most common arrhythmia and is associated with substantial cardiovascular morbidity and mortality, with stroke being the most critical complication. Present drugs used for the therapy of AF (antiarrhythmics and anticoagulants) have major limitations, including incomplete efficacy, risks of life-threatening proarrhythmic events and bleeding complications. Non-pharmacological ablation procedures are efficient and apparently safe, but the very large size of the patient population allows ablation treatment of only a small number of patients. These limitations largely result from limited knowledge about the underlying mechanisms of AF and there is a hope that a better understanding of the molecular basis of AF may lead to the discovery of safer and more effective therapeutic targets. This article reviews the current knowledge about AF-related ion-channel remodelling and discusses how these alterations might affect the efficacy of antiarrhythmic drugs.
No takes yet. Share an insight, caveat, or question.
Voigt et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: